Is Rein Therapeutics Inc (RNTX) overvalued? · $80.6M cap
Rein Therapeutics Inc (RNTX) is a biotechnology company listed on NASDAQ.
This page asks whether Rein Therapeutics Inc (RNTX) looks expensive on cached numbers — not a short thesis.
Latest reported RNTX revenue for 2026-06-30 was $0. Net income was -$12.2M. RNTX currently screens at market cap $80.6M.
RNTX currently screens at market cap $80.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RNTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RNTX stock page for the full model, not this heading.
Not investment advice.